Page last updated: 2024-08-21

quinazolines and tandutinib

quinazolines has been researched along with tandutinib in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (51.28)	29.6817
2010's	17 (43.59)	24.3611
2020's	2 (5.13)	2.80

Authors

Authors	Studies
Abe, K; Amaral, SM; Apatira, M; Boulton, CL; Curley, DP; Duclos, N; Giese, NA; Gilliland, DG; Hollenbach, S; Kelly, LM; Li, J; Lokker, NA; Neuberg, D; Pandey, A; Scarborough, RM; Sullivan, CM; Williams, I; Yu, JC	1
Abe, K; Giese, NA; Hollenbach, SJ; Hutchaleelaha, A; Lambing, JL; Pandey, A; Rose, JW; Scarborough, RM; Seroogy, JM; Volkots, DL; Yu, JC	1
Braziel, RM; Deininger, MW; Demehri, S; Druker, BJ; Giese, N; Griswold, IJ; Haley, AD; Heinrich, MC; La Rosée, P; McGreevey, L; Shen, LJ	1
Clark, JJ; Cools, J; Curley, DP; Giese, NA; Gilliland, DG; Lokker, NA; Yu, JC	1
Corbin, AS; Deininger, MW; Druker, BJ; Griswold, IJ; Heinrich, MC; La Rosée, P; Reimer, CL; Yee, KW	1
Deininger, MW; Druker, BJ; Heinrich, MC; Stoffregen, EP; Walters, DK	1
Naito, K; Ohnishi, K	1
Bassères, DS; Bohlander, SK; Davis, RJ; Dayaram, T; Delmotte, MH; Giese, NA; Gilliland, DG; Hiddemann, W; Lokker, N; Radomska, HS; Schnittger, S; Small, D; Sternberg, DW; Tenen, DG; Yamamoto, Y; Zhang, P; Zheng, R	1
Kiyoi, H	4
Caligiuri, MA; Cooper, MR; Curtin, PT; DeAngelo, DJ; Druker, BJ; Heaney, ML; Heinrich, MC; Holford, N; Karol, MD; Klisovic, RB; Lecerf, JM; Nimer, SD; Paquette, RL; Sheng, S; Stone, RM	1
Jordis, U; Knesl, P; Röseling, D	1
Cheng, Y; Paz, K	1
Brownlow, N; Dibb, NJ; Vaid, M	1
Ehninger, G; Illmer, T	1
Gary Gilliland, D; Tam, WF	1
Bullinger, L; Chen, J; Fröhling, S; Gilliland, DG; Golub, TR; Gu, TL; Lee, BH; Monti, S; Tam, WF; Wang, A	1
Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW	1
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP	1
Balani, SK; Gan, L; Lee, FW; Liao, M; Liu, N; Milton, MN; Prakash, S; Wu, JT; Xia, CQ; Yang, JJ; Yu, S	1
Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Garcia, JA; Rini, BI; Shepard, DR	1
Fine, HA; Floeter, MK; Iwamoto, FM; Kreisl, TN; Lehky, TJ	1
Bekele, BN; Guo, CC; Marcott, V; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM; Wen, S	1
Beausoleil, S; Druker, BJ; Gu, TL; Gygi, SP; Heinrich, MC; Kornhauser, J; Loriaux, M; MacNeill, J; Nardone, J; Polakiewicz, RD; Ren, J; Rush, J; Tucker, M; Villén, J; Wang, Y	1
Abraham, J; Davare, MA; Giles, FJ; Hanes, MA; Keller, C; Kilcoyne, A; Lal, S; Nelon, LD; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP	1
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P	1
Pfister, C; Pfrommer, H; Roser, F; Tatagiba, MS	1
Ponnurangam, S; Rangarajan, P; Standing, D; Subramaniam, D	1
Chen, HF; Chen, JJ; Chen, ZS; Dai, CL; Deng, W; Fu, LW; Kathawala, RJ; Sun, YL	1
Ambudkar, SV; Chen, JJ; Chen, ZS; Dai, CL; Deng, W; Fu, LW; Liang, YJ; Ohnuma, S; Zeng, MS; Zhao, XQ	1
Boult, JK; Bradley, DP; Robinson, SP; Terkelsen, J; Walker-Samuel, S	1
Hu, B; Mohty, M; Savani, BN; Vikas, P	1
Butman, JA; Fine, HA; Iwamoto, FM; Kreisl, TN; Odia, Y; Shih, JH; Sul, J	1
Batchelor, TT; Chowdhary, S; Desideri, S; Duda, DG; Gerstner, ER; Grossman, S; Lesser, GJ; Peereboom, D; Supko, JG; Wen, PY; Ye, X	1
Gray, NS; Hellwig, S; Liu, Y; Smithgall, TE; Tan, L; Weir, MC	1
Abdelhameed, AS; Al-Shakliah, NS; Attwa, MW; Kadi, AA	1
Al-Shakliah, NS; AlRabiah, H; Attwa, MW; Kadi, AA	1

Reviews

8 review(s) available for quinazolines and tandutinib

Article	Year
[Current and new therapeutic strategies in acute myeloid leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine	2005
[Possibility of targeting FLT3 kinase for the treatment of leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:3 Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib	2005
[Novel molecularly target therapies for leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1 Topics: Antineoplastic Agents; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia; Piperazines; Quinazolines; Staurosporine	2007
Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:1 Topics: Administration, Oral; Animals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines	2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1 Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib	2007
Can FLT3 inhibitors overcome resistance in AML? Best practice & research. Clinical haematology, 2008, Volume: 21, Issue:1 Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine	2008
[FLT3 kinase inhibitors for the treatment of acute leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:6 Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine	2010
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert review of hematology, 2014, Volume: 7, Issue:2 Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous	2014

Trials

5 trial(s) available for quinazolines and tandutinib

Article	Year
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 2006, Dec-01, Volume: 108, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Marrow; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Quinazolines; Receptors, Platelet-Derived Growth Factor	2006
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Ohio; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome	2012
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Quinazolines; Receptors, Platelet-Derived Growth Factor; Survival Rate	2011
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS oncology, 2016, Volume: 5, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Quinazolines	2016
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-oncology, 2017, 04-01, Volume: 19, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Tissue Distribution; Treatment Outcome	2017

Other Studies

26 other study(ies) available for quinazolines and tandutinib

Article	Year
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer cell, 2002, Volume: 1, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface; Receptors, Platelet-Derived Growth Factor; Tandem Repeat Sequences; Transfection; Tumor Cells, Cultured	2002
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. Journal of medicinal chemistry, 2002, Aug-15, Volume: 45, Issue:17 Topics: Administration, Oral; Animals; Biological Availability; Dogs; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myelomonocytic, Chronic; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Mutation; Phosphorylation; Piperazines; Plasma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Rats; Rats, Inbred Lew; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Tumor Cells, Cultured	2002
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, Nov-01, Volume: 104, Issue:9 Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Colony-Forming Units Assay; Female; fms-Like Tyrosine Kinase 3; Graft Survival; Humans; Male; Mice; Mice, Inbred BALB C; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor Protein-Tyrosine Kinases; Tandem Repeat Sequences; Transplantation, Homologous	2004
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood, 2004, Nov-01, Volume: 104, Issue:9 Topics: Animals; Cell Line; Cell Survival; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Mice; Mutation; Mutation, Missense; Pharmacogenetics; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Sequence Deletion; Transduction, Genetic	2004
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood, 2004, Dec-01, Volume: 104, Issue:12 Topics: Animals; Cell Line; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mice; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Pyrimidines; Quinazolines	2004
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood, 2005, Apr-01, Volume: 105, Issue:7 Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Transfection	2005
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. The Journal of experimental medicine, 2006, Feb-20, Volume: 203, Issue:2 Topics: Aged; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Granulocytes; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Myeloid Cells; Phosphorylation; Piperazines; Point Mutation; Quinazolines; Serine; Tumor Cells, Cultured; U937 Cells	2006
[The present status of, and problems with the development of FLT3 kinase inhibitors]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:4 Topics: Adult; Cell Cycle Proteins; Chaperonins; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Mutation; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Staurosporine	2006
Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib. Molecules (Basel, Switzerland), 2006, Apr-10, Volume: 11, Issue:4 Topics: Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Magnetic Resonance Spectroscopy; Piperazines; Protein Kinase Inhibitors; Quinazolines	2006
Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia, 2008, Volume: 22, Issue:7 Topics: Animals; Cell Line; Humans; Interleukin-3; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Osteoclasts; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction	2008
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood, 2008, Sep-01, Volume: 112, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitor of Differentiation Protein 1; K562 Cells; Leukemia; Leukemia, Experimental; Mice; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; RNA, Small Interfering; Signal Transduction	2008
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell cycle (Georgetown, Tex.), 2009, Aug-15, Volume: 8, Issue:16 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines	2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, Oct-01, Volume: 114, Issue:14 Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays	2009
P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug metabolism letters, 2010, Volume: 4, Issue:4 Topics: Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Brain; Caco-2 Cells; Humans; Injections, Intravenous; Intestinal Mucosa; Male; Mice; Mice, Knockout; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines	2010
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology, 2011, Jan-18, Volume: 76, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Electromyography; Female; Glioblastoma; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Diseases; Neuromuscular Junction; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Syndrome	2011
Survey of activated FLT3 signaling in leukemia. PloS one, 2011, Apr-28, Volume: 6, Issue:4 Topics: Bone Marrow Cells; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphoamino Acids; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Signal Transduction	2011
Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:2 Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Separation; Cerebellar Neoplasms; Disease Models, Animal; Flow Cytometry; Immunohistochemistry; Medulloblastoma; Mice; Mice, Transgenic; Piperazines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia, 2012, Volume: 26, Issue:7 Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured	2012
Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10 Topics: Angiogenic Proteins; Cell Proliferation; Humans; Indoles; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor A; Xanthones	2012
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2013
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology reports, 2013, Volume: 29, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Inhibitory Concentration 50; Multidrug Resistance-Associated Proteins; Paclitaxel; Piperazines; Quinazolines; Vincristine	2013
Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Jun-14, Volume: 49, Issue:3 Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Humans; Mice; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; NIH 3T3 Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rhodamine 123	2013
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment. PloS one, 2013, Volume: 8, Issue:4 Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Contrast Media; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Female; Glioma; Humans; Mice; Mice, Nude; Piperazines; Quinazolines; Rats; Xenograft Model Antitumor Assays	2013
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. PloS one, 2017, Volume: 12, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fes; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Tandem Repeat Sequences	2017
LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. Drug design, development and therapy, 2020, Volume: 14 Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Microsomes, Liver; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tandem Mass Spectrometry	2020
Identification and characterization of Analytical methods : advancing methods and applications, 2021, 01-28, Volume: 13, Issue:3 Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Mass Spectrometry; Piperazines; Quinazolines; Rats; Rats, Sprague-Dawley	2021